Skip to main content

quinidine

Generic: QUINIDINE SULFATE·Brand: CIN-QUIN, Nuedexta, QUINIDEX, QUINIDINE SULFATE, QUINORA

quinidine: 3 clinical trials tracked.

quinidine evidence translation

What we can confirm

3 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about quinidine, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 3 study sponsors
Clinical Trials (3)

A Non-Randomized, Open-Label, Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine, and Fluconazole on the Pharmacokinetics and Safety of EDP-323 in Healthy Participants

NCT06847464·Phase 1·ENTA
Completed

Primary endpoint: Cmax of EDP-323 with and without coadministration with Itraconazole

Interventionalopen48 enrolledStarted 2025-01Completion 2025-061 site · United StatesEnanta Pharmaceuticals, Inc

A Drug-Drug Interaction, Single-arm, Open-label Study to Assess the Effect of Quinidine on the Pharmacokinetics of Orforglipron in Healthy Participants

NCT06704763·Phase 1·LLY
Completed

Primary endpoint: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Orforglipron

Interventionalopen27 enrolledStarted 2024-12Completion 2025-021 site · United StatesEli Lilly and Company

A Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Tolerability of NX-5948 Tablets Following Single and Multiple Ascending Doses, the Relative Bioavailability of NX-5948 Tablets Compared to Capsules, the Effect of NX-5948 on the QT Interval, the Effect of Food on the Pharmacokinetics of NX-5948, Drug-Drug Interactions With NX-5948, and the Intra-Subject Variability of the Bioavailability of NX-5948 Capsules

NCT06717269·Phase 1·NRIX
Completed

Primary endpoint: Area under the concentration-time curve from time 0 to last observed non-zero concentration (AUC0-t): NX-5948

Interventionalopen223 enrolledStarted 2024-11Completion 2026-052 sites · United StatesNurix Therapeutics, Inc.